Table 1

Baseline characteristics of women and men with severe as before AVR

Study	Study type*	Intervention	Patient (F%)	Age (years, mean)		BSA (m², mean)		STS score (%, mean) or EuroSCORE^Δ		Smoke (%)		Prior CABG (%)		Prior PCI or prior myocardial infarction (%)		Prior stroke (%)		CKD (%)		NYHA III/IV (%)		HTN (%)		DM (%)
Study	Study type*	Intervention	Patient (F%)	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M	F	M
Chaker et al 27	1	SAVR	166 809 (37)	70±13	67±14									44	53			11	14			65	63	27	25.2
William et al 4	3	SAVR and TAVI	699 (43)	84.5±6.3	82.9±7.1	1.69	1.93	11.9	11.8	34	61	19	60	27	38			10	25	94	95			35	47.8
Szerlip et al 47	3	TAVI	1661 (40)	82.5±7.2	82.0±7.1	1.8	2.0	6.8	6.3	36	62	10	43	25	38	16	18	6.5	11			93	93	31	35.2
Chandrasekhar et al 23	2	TAVI	23 652 (50)	82.3±8.5	81.7±8.6	1.7	1.9	9	8	4	6	16	46	30	42	12	13	3.4	4.8	82	80			35	39.5
Doshi et al 32	1	TAVI	8210 (48)	81.7±8.1	80.5±9.1					20	34			9.8	16							80	79	33	35.9
Sannino et al 39	1	TAVI	910 (46)	82.0±7.6	80.9±8.4	1.75	2.02	7.9	7.1			37	57					45	48			88	83	38	42
Saad et al 43	4	TAVI	47 188 (49)	82.7±1.2	81.8±1.4							16	46	30	42	13	15	31	27	83	81	90	88	35	38.6
Vlastra et al 33	1	TAVI	12 381 (58)	83	82			6.7	6.0			6	20	17	27	10	12	14	11			81	76	29	34

*1: retrospective observational study. 2: prospective observational study. 3: secondary analysis of randomised controlled study. 4: meta-analysis study.
AVR, aortic valve replacement; BSA, body surface area; CABG, coronary artery bypass grafting; CKD, chronic kidney dysfunction; DM, diabetes mellitus; EuroSCORE, European System for Cardiac Operative Risk Evaluation score; F, female; HTN, hypertension; M, male; NYHA, New York Heart Association Functional Classification; PCI, percutaneous coronary intervention; SAVR, surgical aortic valve replacement; STS score, Society of Thoracic Surgeon Score; TAVI, transcatheter aortic valve implantation.